| Diabetic nephropathy: A twisted thread to unravel N Dagar, P Das, P Bisht, AK Taraphdar, R Velayutham, S Arumugam Life Sciences 278, 119635, 2021 | 42 | 2021 |
| How to use COVID-19 antiviral drugs in patients with chronic kidney disease A Kale, V Shelke, N Dagar, HJ Anders, AB Gaikwad Frontiers in pharmacology 14, 1053814, 2023 | 23 | 2023 |
| Receptor-mediated mitophagy: An emerging therapeutic target in acute kidney injury N Dagar, A Kale, S Steiger, HJ Anders, AB Gaikwad Mitochondrion 66, 82-91, 2022 | 23 | 2022 |
| Klotho restoration via ACE2 activation: A potential therapeutic strategy against acute kidney injury-diabetes comorbidity A Kale, V Shelke, H Sankrityayan, N Dagar, AB Gaikwad Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1868 (12), 166532, 2022 | 15 | 2022 |
| Potential targets in constipation research: a review P Bisht, N Dagar, N Kumar, R Velayutham, S Arumugam Current Drug Targets 24 (3), 247-260, 2023 | 10 | 2023 |
| Concomitant inhibition of TLR-4 and SGLT2 by phloretin and empagliflozin prevents diabetes-associated ischemic acute kidney injury V Shelke, A Kale, N Dagar, T Habshi, AB Gaikwad Food & Function 14 (11), 5391-5403, 2023 | 10 | 2023 |
| Nutraceuticals and network pharmacology approach for acute kidney injury: a review from the drug discovery aspect N Dagar, A Kale, HR Jadhav, AB Gaikwad Fitoterapia 168, 105563, 2023 | 9 | 2023 |
| Renoprotective effect of esculetin against ischemic acute kidney injury-diabetic comorbidity N Dagar, T Habshi, V Shelke, HR Jadhav, AB Gaikwad Free radical research 58 (2), 69-87, 2024 | 7 | 2024 |
| ER stress modulated Klotho restoration: A prophylactic therapeutic strategy against acute kidney injury-diabetes comorbidity A Kale, V Shelke, T Habshi, N Dagar, AB Gaikwad Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1870 (1), 166905, 2024 | 6 | 2024 |
| Phloretin as an add-on therapy to losartan attenuates diabetes-induced AKI in rats: a potential therapeutic approach targeting TLR4-induced inflammation V Shelke, N Dagar, AB Gaikwad Life Sciences 332, 122095, 2023 | 6 | 2023 |
| Network pharmacology combined with molecular docking and dynamics to assess the synergism of esculetin and phloretin against acute kidney injury-diabetes comorbidity N Dagar, HR Jadhav, AB Gaikwad Molecular Diversity, 1-19, 2024 | 3 | 2024 |
| Metabolic reprogramming: Unveiling the therapeutic potential of targeted therapies against kidney disease S Saxena, N Dagar, V Shelke, M Lech, P Khare, AB Gaikwad Drug Discovery Today 28 (11), 103765, 2023 | 2 | 2023 |
| Molecular insights into P2X signalling cascades in acute kidney injury S Mishra, V Shelke, N Dagar, M Lech, AB Gaikwad Purinergic Signalling 20 (5), 477-486, 2024 | 1 | 2024 |
| Natriuretic peptide system in hypertension: Current understandings of its regulation, targeted therapies and future challenges V Shelke, N Dagar, B Puri, AB Gaikwad European Journal of Pharmacology 976, 176664, 2024 | 1 | 2024 |
| Targeting polo‐like kinase 1 to treat kidney diseases H Kulkarni, N Dagar, AB Gaikwad Cell Biochemistry and Function 42 (5), e4099, 2024 | 1 | 2024 |
| Wnt/beta-catenin modulation: A promising frontier in chronic kidney disease management S Saxena, N Dagar, V Shelke, B Puri, AB Gaikwad Fundamental & clinical pharmacology, 2024 | 1 | 2024 |
| Management of inflammaging in kidney diseases: focusing on the current investigational drugs V Shelke, N Dagar, M Lech, AB Gaikwad Expert Opinion on Investigational Drugs 33 (11), 1153-1166, 2024 | | 2024 |
| ULK1 as a therapeutic target in kidney diseases: Current perspective S Shreya, N Dagar, V Shelke, B Puri, AB Gaikwad Expert Opinion on Therapeutic Targets 28 (10), 911-922, 2024 | | 2024 |
| Immunosuppressants against acute kidney injury: what to prefer or to avoid? S Mishra, V Shelke, N Dagar, M Lech, AB Gaikwad Immunopharmacology and Immunotoxicology 46 (3), 341-354, 2024 | | 2024 |
Dr Gaikwad Anil BhanudasProfessor, Department of Pharmacy Birla Institute of Technology and Science, Pilaniยืนยันอีเมลแล้วที่ pilani.bits-pilani.ac.in